CONFERENCE DAY TWO
8:00 am Digital Networking Room Opens
8:25 am Chair’s Opening Remarks
Mobilizing Novel Drugs Against the Hippo Pathway to Achieve Effective & Sustained Inhibition of TEAD
8:30 am Developing Effective Covalent Inhibitors Against TEAD as Candidates for Cancer Therapy
9:00 am Preclinical Aspects of HM100385 as a Novel & Non-Covalent YAP/TAZ-TEAD Inhibitor: Therapeutic Potential for Hippo-Pathway Altered Cancers
9:15 am Revealing Pre-Clinical Findings for TYK 1054 to Target the Hippo/TEAD Pathway
9:45 am Advancing a pan-TEAD PPI Inhibitor of the YAP/TEAD Complex to Tackle Mesothelioma Through Protein Liquid-Liquid Phase Separation
10:15 am Morning Break & Virtual Networking
Predicting Clinical Patient Sensitivity for Hippo-Targeted Drugs Using Fit-For-Purpose Pre- Clinical Models to Improve Patient Selection
10:45 am Preclinical Approaches for Predicting Sensitivity to YAP/TAZ-TEAD Inhibition in Cancer
11:15 am Panel Discussion: How Can We Use Pre-Clinical Models to Accelerate the Translation of Hippo-Targeted Drugs Towards the Clinic?
12:00 pm Pre-Clinical Mesothelioma Platform to Evaluate Hippo Pathway Targeting Compounds
12:30 pm Lunch Break & Virtual Networking
Tackling Late-Stage Preclinical & Early Clinical Challenges to Expedite TEAD Inhibitors to the Clinic
Chair: Melanie Frigault, Consultant, Translational Medicine, Vincerx Pharma